Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
[HTML][HTML] Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of …
RP Riechelmann, V Srimuninnimit, R Bordonaro… - Clinical colorectal …, 2019 - Elsevier
Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
[HTML][HTML] Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II …
Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …
Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer: Safety and efficacy in a real-life population
E González-Flores, B González-Astorga… - Annals of …, 2017 - annalsofoncology.org
Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer:
Safety and efficacy in a real-life po Page 1 of Epidemiology and Biostatistics, University of Tokyo …
Safety and efficacy in a real-life po Page 1 of Epidemiology and Biostatistics, University of Tokyo …
[HTML][HTML] FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line
therapy in patients with metastatic colorectal cancer. METHODS This is a retrospective …
therapy in patients with metastatic colorectal cancer. METHODS This is a retrospective …
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - Wiley Online Library
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
[HTML][HTML] Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience
D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - mdpi.com
Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
FOLFIRI3-aflibercept as second-or later-line therapy in patients with metastatic colorectal cancer.
817 Background: The efficacy of the standard FOLFIRI-aflibercept second-line therapy may
be improved by the chemotherapy regimen in metastatic colorectal cancer (MCRC). FOLFIRI …
be improved by the chemotherapy regimen in metastatic colorectal cancer (MCRC). FOLFIRI …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program
M Salgado Fernandez, MT Perez Hoyos… - Expert Opinion on …, 2015 - Taylor & Francis
Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …